NeuroSense Therapeutics
NRSN
11 hedge funds and large institutions have $181K invested in NeuroSense Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.
1.96% less ownership
Funds ownership: 2.8% → 0.84% (-2%)
15% less funds holding
Funds holding: 13 → 11 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
77% less capital invested
Capital invested by funds: $776K → $181K (-$595K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HC
Hurley Capital
New York
|
+$9.64K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.52K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$1.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$305K |
| 2 |
Jane Street
New York
|
-$77.6K |
| 3 |
HF
HRT Financial
New York
|
-$77K |
| 4 |
Morgan Stanley
New York
|
-$57.6K |
| 5 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
-$24K |
NRSN Hedge Fund Activity: Q1 2025 in Review
11 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q1 2025, worth a combined $181K — down 77% from $776K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NRSN and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Hurley Capital, opening a new position worth an estimated $9.64K. The largest seller was Citadel Advisors, exiting entirely with an estimated $305K sold.
- 11 institutional investors held NeuroSense Therapeutics (NRSN) as of Q1 2025, down from 13 in Q4 2024.
- Funds reported $181K of NeuroSense Therapeutics stock for Q1 2025, down 77% quarter-over-quarter.
- 2 funds opened new NeuroSense Therapeutics positions in Q1 2025 and 4 closed out, a net change of -2 holders.
- The largest NeuroSense Therapeutics buyer in Q1 2025 was Hurley Capital, an estimated $9.64K added.
- The largest NeuroSense Therapeutics seller in Q1 2025 was Citadel Advisors, an estimated $305K sold.
Based on aggregated 13F filings for Q1 2025.